New data from “INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in PAH” was presented last week during the 39th International Society for Heart and Lung Transplantation Annual Meeting and Scientific Sessions in Orlando, Fla., by principal investigator Nicholas Hill, M.D., from Tufts University School of Medicine in Boston.
The INSPIRE trial is investigating the safety and effectiveness of LIQ861, an inhaled dry powder form of treprostinil. Study participants had pulmonary arterial hypertension (World Health Association Group 1 PH or PAH) and were stable on two or fewer oral PAH therapies. People with PAH were also included if they were transitioning from another form of inhaled treprostinil. Of the 109 patients enrolled in the study, 93% (101 patients) completed at least two months of treatment with LIQ861. Dr. Hill stated that the data thus far is “highly encouraging” for a convenient inhaled PAH therapy.
Side effects reported in 4% or more of study participants were consistent with inhaled prostacyclins and included cough, headache, throat irritation/pain, dizziness, diarrhea, nausea, shortness of breath, flushing and chest discomfort.
Liquidia Technologies, Inc., sponsor of the INSPIRE trial, anticipates submission of a New Drug Application to the U.S. Food and Drug Administration in late 2019.
Interested in participating in a clinical trial investigating potential new PH therapies? Check out PHA’s new Clinical Trial Finder to explore active trials and talk to your PH health care professional about whether clinical research participation is right for you. For more information, contact gro.noitaicossAHP@lacidem.